<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854137</url>
  </required_header>
  <id_info>
    <org_study_id>18434</org_study_id>
    <nct_id>NCT02854137</nct_id>
  </id_info>
  <brief_title>Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes</brief_title>
  <official_title>Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the human eye irritation potential of a test sunscreen formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2015</start_date>
  <completion_date type="Actual">October 14, 2015</completion_date>
  <primary_completion_date type="Actual">October 14, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macroscopic evaluations for Lacrimation (score 0-4)</measure>
    <time_frame>up to 1 hour post instillation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Macroscopic evaluations for Bulbar Conjuctiva Irritation (score 0-3)</measure>
    <time_frame>up to 1 hour post instillation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Macroscopic evaluations of Palpebral Conjunctiva Irritation (score 0-3)</measure>
    <time_frame>up to 1 hour post instillation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective assessment of discomfort (score 0-4)</measure>
    <time_frame>up to 1 hour post instillation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Sunscreening Agents</condition>
  <arm_group>
    <arm_group_label>Sunscreen / Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or steriled dropper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY987521</intervention_name>
    <description>10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).</description>
    <arm_group_label>Sunscreen / Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be healthy males or females between the ages of 18 to 60 years
             inclusive.

          -  Subjects do not wear contact lenses or willing to refrain from wearing them during the
             day of and day after the study.

          -  Subjects are willing to report any medications taken during the study and refrain from
             taking any medication during the study.

          -  Subjects are willing to have the test materials instilled into the eyes and follow all
             protocol requirements.

        Exclusion Criteria:

          -  Subjects have ocular disease or peri-orbital dermatitis or trauma.

          -  Subjects have a systemic illness which contra-indicates participation.

          -  Subjects must not have a history of pre-existing sensitivity or other types of allergy
             to any eye products.

          -  Subjects must not have a history of allergies or sensitivities to cosmetics,
             toiletries, dermatological products, or any ingredients contained in the test or
             control products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

